<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4685"><DrugName>YM-337</DrugName><DrugSynonyms><Name><Value>YM-337</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>YM-387</Value><Types><Type>Research Code</Type><Type>Prodrug</Type></Types></Name><Name><Value>C4G1 antibody</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SMART anti-platelet</Value></Name><Name><Value>anti-gpIIb/IIIa (platelet) MAb, Yamanouchi</Value></Name></DrugSynonyms><CompanyOriginator id="20967">Yamanouchi Pharmaceutical Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Company id="21283">Astellas Pharma Europe BV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4685" type="Drug"><TargetEntity id="230591" type="siDrug">Tadocizumab</TargetEntity></SourceEntity><SourceEntity id="21283" type="Company"><TargetEntity id="4298325558" type="organizationId">Astellas Pharma Europe BV</TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="325">Thromboembolism</Indication><Indication id="65">Stroke</Indication></IndicationsSecondary><ActionsPrimary><Action id="402">GP IIb IIIa antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="312">Platelet aggregation inhibitor</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><EphmraCodes><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra><Ephmra><Code>B1C3</Code><Name>GP IIb/IIIa (glycoprotein) antagonist platelet aggregation inhibitors</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T05:42:28.000Z</LastModificationDate><ChangeDateLast>2017-02-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Yamanouchi was developing &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; (C4G1), a gpIIb/IIIa receptor-specific monoclonal antibody humanized under an agreement with Protein Design Labs (PDL), for the potential treatment of coronary artery disease, including myocardial infarction, arterial thrombosis and ischemic stroke [&lt;ulink linkID="194242" linkType="reference"&gt;194242&lt;/ulink&gt;]. By June 1999, phase II trials of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt;, involving high-risk percutaneous transluminal coronary angioplasty (PTCA) patients, were ongoing in Europe and the US [&lt;ulink linkID="326891" linkType="reference"&gt;326891&lt;/ulink&gt;]. Phase II trials for the potential treatment of ischemic stroke were also underway by May 2001 in Europe and the US [&lt;ulink linkID="411763" linkType="reference"&gt;411763&lt;/ulink&gt;]. Phase II trials for both these indications were ongoing in November 2003 [&lt;ulink linkID="513094" linkType="reference"&gt;513094&lt;/ulink&gt;]; however, development had been discontinued by February 2004 due to its safety and efficacy having been determined to be equivalent to those of existing products. The company was seeking to outlicense &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; at this time [&lt;ulink linkID="522664" linkType="reference"&gt;522664&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In a phase I study involving healthy volunteers, completed by August 1999, the effect of iv bolus injections of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; (0.025, 0.05, 0.1, 0.2 and 0.4 mg/kg) were determined. The 0.2 and 0.4 mg/kg doses inhibited fibrinogen binding by 60 to 70% and 70 to 80%, respectively. After continuous iv infusion of 0.5, 0.75, 1.0 and 1.5 microg/ml, all doses reduced fibrinogen binding by 30% in the first 15 min which lasted over the time of the infusion [&lt;ulink linkID="338793" linkType="reference"&gt;338793&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2003, preclinical data comparing the antithrombotic effects of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; and &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; (qv) in squirrel monkeys were presented at the 19th ISTH conference in Birmingham, UK. &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; (3-12 microg/kg/min) and &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; (0.75-3 microg/kg/min) dose-dependently inhibited ADP-induced ex vivo platelet aggregation in equivalent degrees; &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; (6 &amp;amp; 12 microg/kg/min), &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; (3 microg/kg/min) and aspirin significantly inhibited AA-induced ex-vivo platelet aggregation. Both &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; and &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; dose-dependently occupied platelet GP IIb/IIIa receptors with 90% occupancy achieved at the highest dose. At the highest dose, both drugs prolonged the time to occlusion in animals with electrical stimulation (ES)-induced carotid artery thrombi, no occlusion was observed at the highest dose of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt;. &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt;, &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; and aspirin prevented a reduction in carotid artery blood flow in monkeys with (ES)-induced carotid artery thrombi. The wet thrombus mass decreased dose-dependently in both drug groups. Finally, there was a significant prolongation of the bleeding time in the high dose groups of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; and &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt;. The study concluded that the antithrombotic effect of &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; was equivalent to that of &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkID="497850" linkType="reference"&gt;497850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Studies in rhesus monkeys, conducted by Yamanouchi, showed the antibody to completely inhibit platelet aggregation with little prolongation of bleeding time, when compared to results with the marketed antiplatelet antibody &lt;ulink linkID="2745" linkType="Drug"&gt;abciximab&lt;/ulink&gt; (qv). Furthermore, &lt;ulink linkID="4685" linkType="Drug"&gt;YM-337&lt;/ulink&gt; showed improved efficacy [&lt;ulink linkID="194242" linkType="reference"&gt;194242&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The antibody is based on a Yamanouchi murine antibody specific for the gpIIb/IIIa receptor found on human platelets [&lt;ulink linkID="194242" linkType="reference"&gt;194242&lt;/ulink&gt;], [&lt;ulink linkID="180459" linkType="reference"&gt;180459&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By 1998, Yamanouchi had entered into an agreement with PDL, whereby PDL was to humanize Yamanouchi's anti-gpIIb/IIIa monoclonal antibody fragment. Under the agreement, PDL was to receive an upfront fee, milestone payments and royalties on any product sales [&lt;ulink linkID="274540" linkType="reference"&gt;274540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 1999, Lehman Brothers predicted the first major product launch to be in 2005, with sales peaking in 2013 [&lt;ulink linkID="319225" linkType="reference"&gt;319225&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Sridhar Kamath &amp;amp; Gregory YH Lip, University Department of Medicine, City Hospital, Birmingham, UK&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;28 February 2001 &lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The basic pathophysiological process underlying most (acute) vascular disorders is thrombus formation (thrombogenesis), which is intimately linked to atherogenesis. Platelets appear to play a crucial role in atherosclerosis and thrombosis, and the platelet surface receptor, glycoprotein (GP) IIb/IIIa, represents the final common pathway for platelet aggregation by cross-binding fibrinogen. Inhibition of these platelet GPIIb/IIIa receptors results in almost complete platelet inhibition and a reduction in thrombus formation. &lt;/para&gt;&lt;para&gt;Many clinical trials have demonstrated that platelet GPIIb/IIIa inhibitors, such as &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="26997"&gt;Centocor&lt;/ulink&gt;) and &lt;ulink linkType="Drug" linkID="3467"&gt;tirofiban&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18077"&gt;Merck &amp;amp; Co&lt;/ulink&gt;), result in a significant reduction in mortality and morbidity when used in combination with heparin and aspirin in patients with unstable coronary syndromes and those undergoing coronary interventions [&lt;ulink linkType="reference" linkID="404069"&gt;404069&lt;/ulink&gt;]. Nevertheless, the observed benefit of these newer antiplatelet agents is partly offset by a considerable propensity to bleeding, especially when combined with other antithrombotic agents, such as aspirin and heparin. &lt;/para&gt;&lt;para&gt;Currently, new GPIIb/IIIa drugs are being developed which would have better oral bioavailability, shorter half-lives and provide similar or better efficacy with a lower bleeding risk. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; has been designed to obviate some of these limitations of current agents and might be more effective than conventional platelet GPIIb/IIIa inhibitors, such as &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; is a Fab fragment of a chimeric monoclonal antibody against GPIIb/IIIa receptors that inhibits fibrinogen binding to platelets. It is a humanized (SMART) antibody C4G1, which is based on a murine antibody [&lt;ulink linkType="reference" linkID="194242"&gt;194242&lt;/ulink&gt;]; it combines the binding site of a mouse monoclonal antibody with 90% of a human antibody to minimize an immunological response [&lt;ulink linkType="reference" linkID="180459"&gt;180459&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In vitro laboratory experiments demonstrate that &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; inhibits platelet aggregation 2- to 6-fold more efficiently than &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;. Moreover, the shorter half-life of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; implies a more rapid return of platelet aggregation to baseline values, which may translate to greater benefits in clinical use [&lt;ulink linkType="reference" linkID="395872"&gt;395872&lt;/ulink&gt;]. ADP-induced platelet aggregation is reduced to 55.6 and 28.8% of baseline values by low and high dose &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt;, respectively, 4 h after administration in monkeys when compared to 87% of baseline value with saline [&lt;ulink linkType="reference" linkID="395872"&gt;395872&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; exhibited shear dependency with high shear-preferential antiplatelet effect when compared to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; in the whole blood flow system [&lt;ulink linkType="reference" linkID="395880"&gt;395880&lt;/ulink&gt;]. This particular feature of the drug may suggest a potential and vital role in the management of acute coronary syndromes, where high-shear platelet aggregation is likely to be an important factor in the pathogenesis of the condition.&lt;/para&gt;&lt;para&gt;Studies in rhesus monkeys demonstrate improved efficacy of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; when compared to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;, resulting in dose-dependent platelet aggregation with only limited prolongation of bleeding time (a marker of hemorrhagic tendency) [&lt;ulink linkType="reference" linkID="194242"&gt;194242&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; inhibits platelet aggregation by 80% at a free antibody concentration of 11 nM, whereas a 33-fold higher concentration (360 nM) was required to prolong bleeding to 20 min. On the other hand, &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; inhibited platelet aggregation by 80% at a concentration of 1.7 nM, whereas it required only a 6.5-fold higher concentration (11 nM) to prolong bleeding time to 20 min. This observation therefore represents a wider therapeutic window for the former. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; could be potentially beneficial in the treatment of cerebral artery thrombosis and cerebral infarction. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; prevented photochemically-induced occlusive thrombus in monkeys at 1 mg/kg iv followed by 6 microg/kg/min infusions for 60 min [&lt;ulink linkType="reference" linkID="404064"&gt;404064&lt;/ulink&gt;]. When infused intravenously over 24 h, it significantly decreased the infarct area and the subsequent neurological deficit amongst monkeys following experimental photochemical thrombotic occlusion of distal middle cerebral artery [&lt;ulink linkType="reference" linkID="395872"&gt;395872&lt;/ulink&gt;]. When given as an adjunct to tissue plasminogen activator in copper coil-induced coronary thrombosis in rhesus monkeys, &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; significantly shortened the time to reperfusion, and delayed and prevented reocclusion [&lt;ulink linkType="reference" linkID="395877"&gt;395877&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; may be of potential clinical benefit as an adjunct to thrombolysis in patients with acute myocardial infarction. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; has only minor affinity to the alphavbeta3 receptor when compared with &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="404064"&gt;404064&lt;/ulink&gt;]. Preclinical in vitro assessment of inhibitory effects on platelet function parameters demonstrates a 2- to 4-fold stronger potency of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; when compared to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="404064"&gt;404064&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; has also demonstrated similar potency to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; in the inhibition of binding of fibrinogen to purified GPIIb/IIIa [&lt;ulink linkType="reference" linkID="404067"&gt;404067&lt;/ulink&gt;]. In rhesus monkeys, platelet aggregation was restored to 50% within 6 h after a 0.5 mg/kg bolus of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; when compared with 12 to 18 h with similar doses of &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="395881"&gt;395881&lt;/ulink&gt;]. Bleeding time was less prolonged and the time course of receptor occupancy was less sustained compared with &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="395881"&gt;395881&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism &lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; (0.1 mg/kg) is rapidly bound to platelets and no drug appears as free drug in platelet-poor plasma (PPP). After 0.2 and 0.4 mg/kg boluses, excess amounts of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; not platelet-bound appear in the PPP but are rapidly cleared after approximately 4 h. 24 h After the end of infusion, no drug was detectable in PPP and protein rich plasma (PRP) concentrations after the different infusion regimens were of a similar magnitude of approximately 1300 ng/ml [&lt;ulink linkType="reference" linkID="395875"&gt;395875&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;The safety profile of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; appears to be satisfactory with only one case of transient thrombocytopenia and three minor bleeding events occurring in 53 subjects exposed to the drug [&lt;ulink linkType="reference" linkID="395871"&gt;395871&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; effectively inhibits GPIIb/IIIa-mediated platelet aggregation and adhesion in humans and has a similar antiplatelet effect to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="338793"&gt;338793&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; has been studied in healthy volunteers at different iv bolus doses and continuous infusion regimens. Bolus doses (0.2 and 0.4 mg/kg) inhibited fibrinogen binding by 60 to 70 and 70 to 80%, respectively. Continuous infusion of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; (0.5, 0.75, 1.0 and 1.5 microg/ml) all resulted in reduced fibrinogen binding by 30% in the first 15 min, which lasted over the whole time of the infusion [&lt;ulink linkType="reference" linkID="338793"&gt;338793&lt;/ulink&gt;]. Studies in healthy male humans also demonstrated that &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; significantly inhibited platelet adhesion and platelet induced thrombin generation [&lt;ulink linkType="reference" linkID="395875"&gt;395875&lt;/ulink&gt;]. Nevertheless, the best method to monitor GPIIb/IIIa inhibitor therapy is still unclear. Among healthy human volunteers, neither collagen-induced peak aggregation (at a final concentration of 5 microg/ml) nor the time between the addition of collagen and the start of aggregation was significantly altered [&lt;ulink linkType="reference" linkID="395873"&gt;395873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Phase II trials with &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; are being carried out in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients in Europe and the US [&lt;ulink linkType="reference" linkID="326891"&gt;326891&lt;/ulink&gt;]. No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;In phase I trials, &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; was demonstrated to be safer than &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;. Platelet aggregation returns to normal within 24 h and adhesion within 48 h after the cessation of infusion. Bleeding time returns to normal 1 h after bolus injection [&lt;ulink linkType="reference" linkID="395881"&gt;395881&lt;/ulink&gt;] and 4 h after the cessation of infusion [&lt;ulink linkType="reference" linkID="395871"&gt;395871&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 53 subjects exposed to &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt;, there was one case of transient thrombocytopenia, which recovered completely after 96 h, and three minor bleeding events [&lt;ulink linkType="reference" linkID="395871"&gt;395871&lt;/ulink&gt;]. Another phase I study with &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; reported one more case of thrombocytopenia in a subset of 34 exposed subjects (&lt;ulink linkType="Company" linkID="21283"&gt;Yamanouchi Europe BV&lt;/ulink&gt;, Leiderdorp, Netherlands, data on file). No human antichimeric antibodies were detected at two weeks and two months after administration [&lt;ulink linkType="reference" linkID="395875"&gt;395875&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The shorter duration of action of &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt;, more rapid reversal of effects on cessation of therapy, wider therapeutic window and probable decrease in bleeding tendency (in animal models, at least) could potentially make &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; a safer and more potent alternative to &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;. Nevertheless, the results are limited to the typical phase I setting and the possible interactions with drugs administered in clinical situations (for example, aspirin and heparin) are not known. The estimated 2% incidence of thrombocytopenia with &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; is comparable to that reported with &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="395875"&gt;395875&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="404063"&gt;404063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The role of platelets in the etiopathogenesis of the atherothrombotic vascular disorders has drawn great research interest in this area. Inhibition of platelet activation through different mechanisms has proven to be of significant benefit in these vascular disorders. In particular, blockade of GPIIb/IIIa receptors on the platelet surface results in almost complete inhibition of platelet aggregation but may predispose to hemorrhage. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; demonstrates effective antiplatelet activity in human and experimental studies. Thus, &lt;ulink linkType="Drug" linkID="4685"&gt;YM-337&lt;/ulink&gt; is a step forward in the current development of antiplatelet drugs and has potential for future use in various atherothrombotic disorders, especially in acute myocardial infarction (as an adjunct to thrombolytic therapy), acute coronary syndromes and percutaneous coronary interventions. Further phase II and phase III data are needed and are awaited with interest.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="522664" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="522664" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="325">Thromboembolism</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="522664" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="325">Thromboembolism</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="522664" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="325">Thromboembolism</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="522664" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="325">Thromboembolism</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2001-06-07T00:00:00.000Z</StatusDate><Source id="411763" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2001-06-07T00:00:00.000Z</StatusDate><Source id="411763" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>1999-06-07T00:00:00.000Z</StatusDate><Source id="326891" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>1999-06-07T00:00:00.000Z</StatusDate><Source id="326891" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>1997-11-28T00:00:00.000Z</StatusDate><Source id="270568" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21283">Astellas Pharma Europe BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>1997-12-05T00:00:00.000Z</StatusDate><Source id="271325" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00882"><Name>GP IIb IIIa</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1979209" number="EP-00239400" title="Recombinant Antibodies And Methods For Their Production"/><PatentFamily id="456194" number="WO-08403712" title="Multichain polypeptides or proteins and processes for their production"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BTG plc" id="15266"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical Research Council" id="18438"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PDL BioPharma Inc" id="19162"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="XOMA Corp" id="20954"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>